COPENHAGEN, Denmark, Aug. 27, 2025 /CNW/ -- Adcendo, a clinical-stage biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that management will participate in five upcoming investor conferences in September:
Read more at newswire.caThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
